Issues in Assessment of Durability of Success in HIV Clinical Trials
View Presentation View Presentation
*Victor DeGruttola, Harvard School of Public Health 


An issue that arises in research on new treatments for HIV infections is that patients generally change therapies after there is evidence of significant toxicities or loss of potency. While one can define a failure endpoint at the time of treatment change, doing so conflates efficacy and toxicity. Therefore it is important to consider how best to estimate efficacy in the presence of dose-limiting toxicities, newer ideas related to causal inference may be useful in this setting.